Donor pretreatment with carbamylated erythropoietin in a brain death model reduces inflammation more effectively than erythropoietin while preserving renal function

Willemijn N. Nijboer*, Petra J. Ottens, Antony van Dijk, Harry van Goor, Rutger J. Ploeg, Henri G. D. Leuvenink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)


Objective: We hypothesized that donor treatment of deceased brain dead donors would lead to a decrease in inflammatory responses seen in brain death and lead to a restoration of kidney function.

Design: A standardized slow-induction rat brain death model followed by evaluation of kidney function in an isolated perfused kidney model.

Settings: Surgery Research Laboratory, University Medical Center Groningen, the Netherlands.

Subjects: Male Fisher rats.

Interventions: Donor treatment with erythropoietin, carbamylated erythropoietin, which lacks erythropoietic activity, or vehicle.

Measurements and Main Results: In brain death, carbamylated erythropoietin and, to a lesser extent, erythropoietin were able to decrease the expression of several proinflammatory genes and to decrease the infiltration of polymorphonuclear cells in the kidney. No effect on tubular injury parameters was seen. Kidney function decreased almost by 50% after brain death but was fully restored after treatment with both carbamylated erythropoietin and erythropoietin.

Conclusions: Carbamylated erythropoietin can inhibit the inflammatory response caused by brain death more effectively than erythropoietin, whereas both substances can restore kidney function after brain death. (Crit Care Med 2010; 38: 1155-1161)

Original languageEnglish
Pages (from-to)1155-1161
Number of pages7
JournalCritical Care Medicine
Issue number4
Publication statusPublished - Apr-2010


  • donor
  • erythropoietin
  • carbamylated erythropoietin
  • brain death
  • kidney

Cite this